Viking Therapeutics (VKTX) Received its Third Buy in a Row


After Stifel Nicolaus and Raymond James gave Viking Therapeutics (NASDAQ: VKTX) a Buy rating last month, the company received another Buy, this time from BMO Capital. Analyst Matthew Luchini maintained a Buy rating on Viking Therapeutics today and set a price target of $15.00. The company’s shares closed last Wednesday at $6.36.

According to TipRanks.com, Luchini is a 3-star analyst with an average return of 9.1% and a 43.2% success rate. Luchini covers the Healthcare sector, focusing on stocks such as Applied Genetic Technologies, Madrigal Pharmaceuticals, and Arvinas Holding Company.

Currently, the analyst consensus on Viking Therapeutics is a Strong Buy with an average price target of $16.44, representing a 158.5% upside. In a report released yesterday, Stifel Nicolaus also reiterated a Buy rating on the stock with a $13.00 price target.

See today’s analyst top recommended stocks >>

Based on Viking Therapeutics’ latest earnings release for the quarter ending December 31, the company reported a quarterly GAAP net loss of $10.95 million. In comparison, last year the company had a GAAP net loss of $7.45 million.

Based on the recent corporate insider activity of 14 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of VKTX in relation to earlier this year.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of novel therapies for patients suffering from metabolic and endocrine disorders. The company’s clinical program VK5211, treats patients recovering from non-elective hip fracture surgery. It also specializes in development of VK2809 and VK0214. The company was founded by Brian Lian and Michael A. Dinerman on September 24, 2012 and is headquartered in San Diego, CA.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts